870221-49-1

Basic information

• Product Name: 4-(2-Chloropyridin-3-yl)pyrimidin-2-amine
• Synonyms: 4-(2-Chloropyridin-3-yl)pyrimidin-2-amine
• CAS NO: 870221-49-1
• Molecular Formula: C₉H₇ClN₄
• Molecular Weight: 206.63168
• Mol File: 870221-49-1.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(2-Chloropyridin-3-yl)pyrimidin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-Chloropyridin-3-yl)pyrimidin-2-amine(870221-49-1)
• EPA Substance Registry System: 4-(2-Chloropyridin-3-yl)pyrimidin-2-amine(870221-49-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 870221-49-1(Hazardous Substances Data)

Upstream product

• 870221-50-4 (E)-1-(2-chloropyridin-3-yl)-3-(dimethylamino)-prop-2-en-1-one 
• 50-01-1 guanidine hydrochloride 

Downstream Products

• 870221-48-0 N-(4-(2-chloropyridin-3-yl)pyrimidin-2-yl)-4-(4-methylpiperazin-1-yl)benzamide 
• 945595-80-2 AMG 900 
• 945599-45-1 4-(2-(4-aminophenoxy)pyridin-3-yl)pyrimidin-2-amine 

Relevant articles and documents

N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

The present invention relates to methods of using the compound, N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine or a pharmaceutically acceptable salt thereof, to treat cancers, including solid tumors, which have become resistant to treatment with chemotherapeutic agents, including anti-mitotic agents such as taxanes, and/or other anti-cancer agents, including aurora kinase inhibiting agents. The invention also includes methods of treating cancers refractory to such treatments by administering a pharmaceutical composition, comprising the compound to a cancer subject.

CRYSTALLINE FORMS OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL) - 2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL-2-THIENYL)-1 -PHTHALAZINAMINE PHARMACEUTICALLY ACCEPTABLE SALTS AND USES THEREOF

The present invention relates to crystalline forms and co-crystal forms of pharmaceutically acceptable salts of the compound, N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine (AMG 900, and pharmaceutical compositions comprising said crystalline and co-crystal forms thereof. The invention further provides uses of the crystalline foms and compositions, to treat cancer, including various types of solid tumors and hematologic cancer including myeloma and leukemia.

USE OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL) -2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL -2-THIENYL)-1-PHTHALAZINAMINE IN COMBINATION WITH HISTONE DEACETYLASE INHIBITORS FOR TREATMENT OF CANCER

-